b*****h
发帖数: 783 | 1 YMI 是个加拿大的biotech，它本来只有一个EGFR抗体药物－Nimotuzumab,做到后来都
濒临破产了。
后来公司合并了Cytopia, 获得了Cytopia JAK2 inhibitor--CYT387，不过那时CYT387
还在preclinical阶段. JAK inhibitor
目前主要在开发治疗Myeloproliferative Disorder,
(做JAK2 inhibitor 的领头公司是INCY，看看它过去股价的走势就知道大家对JAK
inhibitor的热情。)
YMI 的CYT387正在做phaseI/II的 clinical trial. 因为效果不错。trial的人数扩展
了好几次。
从interim data看，治疗效果和INCY的Ruxolitinib类似，但在对改善anemia的效果比
INCY 的Ruxolitinib还要有希望。
phase II 的fulll data在年底出来。 | c**t
发帖数: 2889 | 2 谢谢，看来值得长期持有
CYT387
【在 b*****h 的大作中提到】
: YMI 是个加拿大的biotech，它本来只有一个EGFR抗体药物－Nimotuzumab,做到后来都
: 濒临破产了。
: 后来公司合并了Cytopia, 获得了Cytopia JAK2 inhibitor--CYT387，不过那时CYT387
: 还在preclinical阶段. JAK inhibitor
: 目前主要在开发治疗Myeloproliferative Disorder,
: (做JAK2 inhibitor 的领头公司是INCY，看看它过去股价的走势就知道大家对JAK
: inhibitor的热情。)
: YMI 的CYT387正在做phaseI/II的 clinical trial. 因为效果不错。trial的人数扩展
: 了好几次。
: 从interim data看，治疗效果和INCY的Ruxolitinib类似，但在对改善anemia的效果比
| X*****s
发帖数: 2767 | | v**********m
发帖数: 5516 | 4 先谢谢biofish提供消息，特别是提供“年底出数据”这个我们可以打埋伏的口袋。
粗粗看了一下价格，觉得现在介入不太划算。
CYT387
【在 b*****h 的大作中提到】
: YMI 是个加拿大的biotech，它本来只有一个EGFR抗体药物－Nimotuzumab,做到后来都
: 濒临破产了。
: 后来公司合并了Cytopia, 获得了Cytopia JAK2 inhibitor--CYT387，不过那时CYT387
: 还在preclinical阶段. JAK inhibitor
: 目前主要在开发治疗Myeloproliferative Disorder,
: (做JAK2 inhibitor 的领头公司是INCY，看看它过去股价的走势就知道大家对JAK
: inhibitor的热情。)
: YMI 的CYT387正在做phaseI/II的 clinical trial. 因为效果不错。trial的人数扩展
: 了好几次。
: 从interim data看，治疗效果和INCY的Ruxolitinib类似，但在对改善anemia的效果比
| L**j
发帖数: 948 | | y****8
发帖数: 421 | | X*****s
发帖数: 2767 | 7 biohope的隆重推荐要给面子
YMI 6*[email protected] | H****a
发帖数: 642 | | b*****h
发帖数: 783 | 9 YMI 在上一轮下跌中已经趋于平稳，它的phase II final data 需要明年初出来，
感觉不管INCY 在12月fda的结果如何，对ymi都是利好， 所以，目前的ymi应该是low
risk player.
CYT387
【在 b*****h 的大作中提到】
: YMI 是个加拿大的biotech，它本来只有一个EGFR抗体药物－Nimotuzumab,做到后来都
: 濒临破产了。
: 后来公司合并了Cytopia, 获得了Cytopia JAK2 inhibitor--CYT387，不过那时CYT387
: 还在preclinical阶段. JAK inhibitor
: 目前主要在开发治疗Myeloproliferative Disorder,
: (做JAK2 inhibitor 的领头公司是INCY，看看它过去股价的走势就知道大家对JAK
: inhibitor的热情。)
: YMI 的CYT387正在做phaseI/II的 clinical trial. 因为效果不错。trial的人数扩展
: 了好几次。
: 从interim data看，治疗效果和INCY的Ruxolitinib类似，但在对改善anemia的效果比
| g***t
发帖数: 1279 | | y*****l
发帖数: 5997 | 11 12/12. Have spt @ 1.75.
YM BioSciences to Report Updated Phase I/II Data for CYT387 at ASH 2011
YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), today announced it would
report updated results from its Phase I/II myelofibrosis study of CYT387, a
JAK1/JAK2 inhibitor, in a poster session to be held from 6:00pm - 8:00pm on
Monday, December 12th at the 53rd Annual Meeting of the American Society of
Hematology (ASH) being held in San Diego, California. The Company also
reported updated results today from the study that were included in an
abstract submitted to ASH in August 2011.
At the time the ASH abstract was submitted, 163 patients had been recruited
into the trial across the six study sites. The duration of treatment ranged
from 0.25 to 20.4 months with a median duration of 6.6 months. Forty six
subjects were transfusion dependent at baseline. Previous JAK inhibitor
therapy was reported for 11% and previous IMiD therapy for 8% of enrolled
subjects. Reductions in spleen size, improvements in constitutional symptoms
and the achievement of transfusion independence were observed in subjects
in the expanded multicenter study.
CYT387 was well tolerated. Seventy three percent of subjects reported
treatment-related adverse events, with the majority reported as Grade 1. The
most common Grade 3-4 treatment related adverse events included
thrombocytopenia and hyperlipasemia, occurring in 16% and 3% of subjects
respectively. Twenty five of 163 (15%) of subjects had discontinued from the
nine month core study, giving a retention rate of 85%.
The authors of the abstract conclude that CYT387 appears to be well
tolerated when administered in either a once or twice-daily dosing regimen,
and shows substantial clinical activity in myelofibrosis, with improvements
in splenomegaly and constitutional symptoms. In addition, CYT387 continues
to demonstrate an ability to induce durable anemia responses in a subset of
subjects.
Poster presentation and YM conference call: Updated results from the Phase I
/II study will be presented in a poster session at the 53rd Annual Meeting
of the American Society of Hematology. Poster #3849, entitled "An Expanded
Multicenter Phase I/II Study of CYT387, a JAK- 1/2 Inhibitor for the
Treatment of Myelofibrosis", will be presented at Session #634,
Myeloproliferative Syndromes: Poster III, to be held on Monday, December
12th from 6:00-8:00pm PT in Hall HG of the San Diego Convention Center. YM
will also host a webcast meeting open to members of the investment community
to discuss these results. This event will be held from 6:30-7:30am PT on
Tuesday, December 13th in the Grand Ballroom of the Hotel Palomar, 1047
Fifth Avenue, San Diego. Access to the webcast will be available from YM's
website at www.ymbiosciences.com.
About CYT387: CYT387 is an inhibitor of the kinase enzymes JAK1 and JAK2,
which have been implicated in a family of hematological conditions known as
myeloproliferative neoplasms, including myelofibrosis, and as well in
numerous other disorders including indications in hematology, oncology and
inflammatory diseases. Myelofibrosis is a chronic debilitating disease in
which a patient's bone marrow is replaced by scar tissue and for which
treatment options are limited or unsatisfactory.
Both the U.S. Food and Drug Administration (FDA) and the European Commission
have designated CYT387 an Orphan Drug for the treatment of myelofibrosis.
YM BioSciences retains full global commercialization rights to CYT387.
About YM BioSciences YM BioSciences Inc. is a drug development company
advancing three products: CYT387, a small molecule, dual inhibitor of the
JAK1/JAK2 kinases; nimotuzumab, an EGFR-targeting monoclonal antibody; and
CYT997, a vascular disrupting agent (VDA).
CYT387 is an orally administered inhibitor of both the JAK1 and JAK2 kinases
, which have been implicated in a number of immune cell disorders including
myeloproliferative neoplasms and inflammatory diseases as well as certain
cancers. CYT387 is currently in a 166 patient Phase I/II trial in
myelofibrosis that has completed enrollment, as well as a 60 patient Phase
II BID trial that is recruiting patients. Nimotuzumab is a humanized
monoclonal antibody targeting EGFR with an enhanced side-effect profile over
currently marketed EGFR-targeting antibodies. Nimotuzumab is being
evaluated in numerous Phase II and III trials worldwide. CYT997 is an orally
-available small molecule therapeutic with dual mechanisms of vascular
disruption and cytotoxicity, and has completed a Phase II trial in
glioblastoma multiforme. In addition to YM's three clinical stage products,
the Company has several preclinical research programs underway with
candidates from its library of novel compounds identified through internal
research conducted at YM BioSciences Australia.
【在 b*****h 的大作中提到】
: YMI 在上一轮下跌中已经趋于平稳，它的phase II final data 需要明年初出来，
: 感觉不管INCY 在12月fda的结果如何，对ymi都是利好， 所以，目前的ymi应该是low
: risk player.
:
: CYT387
|
|
